Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Grape Seed Extracts Blocks Formation of Toxic Amyloid-Beta Oligomers in Brain Tissue

By LabMedica International staff writers
Posted on 27 Jul 2011
Compounds present in grape seed polyphenolic extract (GSPE) may protect against the development of Alzheimer’s disease by blocking the formation of toxic amyloid-beta (A-beta) oligomers in brain tissue.

Previous studies have found that increased consumption of grape-derived polyphenols, such as those found in red wine, may protect against cognitive decline in Alzheimer’s disease. More...
In the current study, investigators at Mount Sinai School of Medicine (New York, NY, USA) and their colleagues at the University of Minnesota (Minneapolis, USA) treated Tg2576 mice – a well-known rodent Alzheimer’s disease model – with GSPE for a period of five months.

They reported in the July 2011 online edition of the Journal of Alzheimer’s Disease that the treatment significantly decreased brain levels of A-beta*56, a 56-kDa A-beta oligomer previously shown to induce memory dysfunction in rodents, without changing the levels of transgenic amyloid-beta protein precursor, monomeric A-beta, or other A-beta oligomers.

“It will be critical to identify subjects who are at high risk of developing Alzheimer’s disease, so that we can initiate treatments very early and possibly even in asymptomatic patients,” said senior author Dr. Giulio Maria Pasinetti, professor of psychiatry and geriatrics at the Mount Sinai School of Medicine. “However, for Alzheimer’s disease patients who have already progressed into the initial stages of the disease, early intervention with this treatment might be beneficial as well. Our study implicating that these neurotoxins such as A-beta*56 in the brain are targeted by grape-derived polyphenols holds significant promise.”

“Since naturally occurring polyphenols are also generally commercially available as nutritional supplements and have negligible adverse events even after prolonged periods of treatment, this new finding holds significant promise as a preventive method or treatment, and is being tested in translational studies in Alzheimer’s disease patients,” said Dr. Pasinetti.

Since the results of this study showed that a safe and affordable intervention could lower the levels of a memory-impairing A-beta oligomer in vivo, the authors strongly suggested that GSPE should be further tested as a potential prevention and/or therapy for Alzheimer’s disease.

Related Links:
Mount Sinai School of Medicine
University of Minnesota


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Human Estradiol Assay
Human Estradiol CLIA Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.